Request a Quote |

Cyprotex expands further in to the United States

Cyprotex expands further in to the United States with the appointment of Global Head of Business Development

Cyprotex PLC, the drug discovery technology and information company, is pleased to announce its further expansion in to the United States. Mitchell Winfree has been appointed the senior role of Global Head of Business Development. His role is further complemented by the additional appointment of a Director of West Coast Business Development. Both will concentrate on capturing North American sales opportunities.

The US is seen to offer a great wealth of opportunities for Cyprotex in terms of key partners, collaborations and customers. With as much as 60% of the early stage global drug development concentrated in North America, an abundance of small and medium-sized biotechs / Contract Research Organisations (CRO’s) and generally greater propensity toward outsourcing services such as high-throughput ADME/Tox screening, this territory has become a principal focus.

Mitchell Winfree becomes Global Head of Business Development and brings international experience in the pharmaceutical and biotechnology industry, having held senior positions at both Absorption Systems LP, a privately held CRO working with Pharmaceuticals and Biotech partners, and PPD, Inc (DNA Sciences, Inc) an applied genetics company focused on the discovery and commercialization of DNA based diagnostic tests

Cyprotex has also appointed an experienced Director of West Coast Business Development, with a view to echoing the success of last year’s similar appointment on the East Coast.

Commenting on these appointments, Robert Morrisson Atwater, CEO of Cyprotex, said: ‘We welcome the new appointments into the Cyprotex Group. Both individuals have significant experience and innovative flair, and will play a substantial role in driving forward sales as the Company enters into an exciting phase of growth and development.”

For further information:

Cyprotex PLC
Robert Morrison Atwater,Chairman and Chief Executive Officer
Tel: +44 (0)1625 505 100

Code Securities Limited
Chris Collins, Corporate Finance
Tel: +44 (0)20 7776 1200

Media Enquires:

Heather Salmond/Georgina Bonham
Tel: +44 (0)20 7398 7700

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: